Proinflammatory cytokines are associated with prolonged viral RNA shedding in COVID-19 patients.
Identifieur interne : 000A15 ( Main/Corpus ); précédent : 000A14; suivant : 000A16Proinflammatory cytokines are associated with prolonged viral RNA shedding in COVID-19 patients.
Auteurs : Chun Gao ; Li Zhu ; Cheng Cheng Jin ; Yi Xin Tong ; Ai Tang Xiao ; Sheng ZhangSource :
- Clinical immunology (Orlando, Fla.) [ 1521-7035 ] ; 2020.
English descriptors
- KwdEn :
- Adrenal Cortex Hormones (therapeutic use), Adult (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), COVID-19 (diagnosis), COVID-19 (drug therapy), COVID-19 (immunology), COVID-19 (virology), China (MeSH), Comorbidity (MeSH), Cytokine Release Syndrome (diagnosis), Cytokine Release Syndrome (drug therapy), Cytokine Release Syndrome (immunology), Cytokine Release Syndrome (virology), Diabetes Mellitus (diagnosis), Diabetes Mellitus (drug therapy), Diabetes Mellitus (immunology), Diabetes Mellitus (virology), Drug Combinations (MeSH), Female (MeSH), Hospitalization (MeSH), Humans (MeSH), Hydroxychloroquine (therapeutic use), Hypertension (diagnosis), Hypertension (drug therapy), Hypertension (immunology), Hypertension (virology), Interferons (therapeutic use), Lopinavir (therapeutic use), Lymphopenia (diagnosis), Lymphopenia (drug therapy), Lymphopenia (immunology), Lymphopenia (virology), Male (MeSH), Middle Aged (MeSH), RNA, Viral (blood), Receptors, Interleukin-2 (biosynthesis), Retrospective Studies (MeSH), Risk Factors (MeSH), Ritonavir (therapeutic use), SARS-CoV-2 (pathogenicity), Severity of Illness Index (MeSH), Tumor Necrosis Factor-alpha (biosynthesis), Virus Shedding (MeSH).
- MESH :
- chemical , biosynthesis : Receptors, Interleukin-2, Tumor Necrosis Factor-alpha.
- chemical , blood : RNA, Viral.
- chemical , therapeutic use : Adrenal Cortex Hormones, Hydroxychloroquine, Interferons, Lopinavir, Ritonavir.
- geographic : China, Drug Combinations.
- diagnosis : COVID-19, Cytokine Release Syndrome, Diabetes Mellitus, Hypertension, Lymphopenia.
- drug therapy : COVID-19, Cytokine Release Syndrome, Diabetes Mellitus, Hypertension, Lymphopenia.
- immunology : COVID-19, Cytokine Release Syndrome, Diabetes Mellitus, Hypertension, Lymphopenia.
- pathogenicity : SARS-CoV-2.
- virology : COVID-19, Cytokine Release Syndrome, Diabetes Mellitus, Hypertension, Lymphopenia.
- Adult, Aged, Aged, 80 and over, Comorbidity, Female, Hospitalization, Humans, Male, Middle Aged, Retrospective Studies, Risk Factors, Severity of Illness Index, Virus Shedding.
Abstract
Since December 2019, Coronavirus Disease 2019 (COVID-19) has emerged as a global pandemic. We aimed to investigate the clinical characteristics and analyzed the risk factors for prolonged viral RNA shedding. We retrospectively collected data from 112 hospitalized COVID-19 patients in a single center in Wuhan, China. Factors associated with prolonged viral RNA shedding (≥28 days) were investigated. Forty-nine (43.8%) patients had prolonged viral RNA shedding. Patients with prolonged viral shedding were older and had a higher rate of hypertension. Proinflammatory cytokines, including interleukin-2R (IL-2R) and tumor necrosis factor-α (TNF-α), were significantly elevated in patients with prolonged viral shedding. Multivariate analysis revealed that hypertension, older age, lymphopenia and elevated serum IL-2R were independent risk factors for prolonged viral shedding. This comprehensive investigation revealed the distinct characteristics between patients with or without prolonged viral RNA shedding. Hypertension, older age, lymphopenia and high levels of proinflammatory cytokines may be correlated with prolonged viral shedding.
DOI: 10.1016/j.clim.2020.108611
PubMed: 33068796
PubMed Central: PMC7554496
Links to Exploration step
pubmed:33068796Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Proinflammatory cytokines are associated with prolonged viral RNA shedding in COVID-19 patients.</title>
<author><name sortKey="Gao, Chun" sort="Gao, Chun" uniqKey="Gao C" first="Chun" last="Gao">Chun Gao</name>
<affiliation><nlm:affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zhu, Li" sort="Zhu, Li" uniqKey="Zhu L" first="Li" last="Zhu">Li Zhu</name>
<affiliation><nlm:affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Jin, Cheng Cheng" sort="Jin, Cheng Cheng" uniqKey="Jin C" first="Cheng Cheng" last="Jin">Cheng Cheng Jin</name>
<affiliation><nlm:affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Tong, Yi Xin" sort="Tong, Yi Xin" uniqKey="Tong Y" first="Yi Xin" last="Tong">Yi Xin Tong</name>
<affiliation><nlm:affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Xiao, Ai Tang" sort="Xiao, Ai Tang" uniqKey="Xiao A" first="Ai Tang" last="Xiao">Ai Tang Xiao</name>
<affiliation><nlm:affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zhang, Sheng" sort="Zhang, Sheng" uniqKey="Zhang S" first="Sheng" last="Zhang">Sheng Zhang</name>
<affiliation><nlm:affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China. Electronic address: aloof3737@126.com.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:33068796</idno>
<idno type="pmid">33068796</idno>
<idno type="doi">10.1016/j.clim.2020.108611</idno>
<idno type="pmc">PMC7554496</idno>
<idno type="wicri:Area/Main/Corpus">000A15</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000A15</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Proinflammatory cytokines are associated with prolonged viral RNA shedding in COVID-19 patients.</title>
<author><name sortKey="Gao, Chun" sort="Gao, Chun" uniqKey="Gao C" first="Chun" last="Gao">Chun Gao</name>
<affiliation><nlm:affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zhu, Li" sort="Zhu, Li" uniqKey="Zhu L" first="Li" last="Zhu">Li Zhu</name>
<affiliation><nlm:affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Jin, Cheng Cheng" sort="Jin, Cheng Cheng" uniqKey="Jin C" first="Cheng Cheng" last="Jin">Cheng Cheng Jin</name>
<affiliation><nlm:affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Tong, Yi Xin" sort="Tong, Yi Xin" uniqKey="Tong Y" first="Yi Xin" last="Tong">Yi Xin Tong</name>
<affiliation><nlm:affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Xiao, Ai Tang" sort="Xiao, Ai Tang" uniqKey="Xiao A" first="Ai Tang" last="Xiao">Ai Tang Xiao</name>
<affiliation><nlm:affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zhang, Sheng" sort="Zhang, Sheng" uniqKey="Zhang S" first="Sheng" last="Zhang">Sheng Zhang</name>
<affiliation><nlm:affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China. Electronic address: aloof3737@126.com.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Clinical immunology (Orlando, Fla.)</title>
<idno type="eISSN">1521-7035</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenal Cortex Hormones (therapeutic use)</term>
<term>Adult (MeSH)</term>
<term>Aged (MeSH)</term>
<term>Aged, 80 and over (MeSH)</term>
<term>COVID-19 (diagnosis)</term>
<term>COVID-19 (drug therapy)</term>
<term>COVID-19 (immunology)</term>
<term>COVID-19 (virology)</term>
<term>China (MeSH)</term>
<term>Comorbidity (MeSH)</term>
<term>Cytokine Release Syndrome (diagnosis)</term>
<term>Cytokine Release Syndrome (drug therapy)</term>
<term>Cytokine Release Syndrome (immunology)</term>
<term>Cytokine Release Syndrome (virology)</term>
<term>Diabetes Mellitus (diagnosis)</term>
<term>Diabetes Mellitus (drug therapy)</term>
<term>Diabetes Mellitus (immunology)</term>
<term>Diabetes Mellitus (virology)</term>
<term>Drug Combinations (MeSH)</term>
<term>Female (MeSH)</term>
<term>Hospitalization (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Hypertension (diagnosis)</term>
<term>Hypertension (drug therapy)</term>
<term>Hypertension (immunology)</term>
<term>Hypertension (virology)</term>
<term>Interferons (therapeutic use)</term>
<term>Lopinavir (therapeutic use)</term>
<term>Lymphopenia (diagnosis)</term>
<term>Lymphopenia (drug therapy)</term>
<term>Lymphopenia (immunology)</term>
<term>Lymphopenia (virology)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>RNA, Viral (blood)</term>
<term>Receptors, Interleukin-2 (biosynthesis)</term>
<term>Retrospective Studies (MeSH)</term>
<term>Risk Factors (MeSH)</term>
<term>Ritonavir (therapeutic use)</term>
<term>SARS-CoV-2 (pathogenicity)</term>
<term>Severity of Illness Index (MeSH)</term>
<term>Tumor Necrosis Factor-alpha (biosynthesis)</term>
<term>Virus Shedding (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Receptors, Interleukin-2</term>
<term>Tumor Necrosis Factor-alpha</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>RNA, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adrenal Cortex Hormones</term>
<term>Hydroxychloroquine</term>
<term>Interferons</term>
<term>Lopinavir</term>
<term>Ritonavir</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>China</term>
<term>Drug Combinations</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>COVID-19</term>
<term>Cytokine Release Syndrome</term>
<term>Diabetes Mellitus</term>
<term>Hypertension</term>
<term>Lymphopenia</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term>
<term>Cytokine Release Syndrome</term>
<term>Diabetes Mellitus</term>
<term>Hypertension</term>
<term>Lymphopenia</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>COVID-19</term>
<term>Cytokine Release Syndrome</term>
<term>Diabetes Mellitus</term>
<term>Hypertension</term>
<term>Lymphopenia</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>COVID-19</term>
<term>Cytokine Release Syndrome</term>
<term>Diabetes Mellitus</term>
<term>Hypertension</term>
<term>Lymphopenia</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Comorbidity</term>
<term>Female</term>
<term>Hospitalization</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Retrospective Studies</term>
<term>Risk Factors</term>
<term>Severity of Illness Index</term>
<term>Virus Shedding</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Since December 2019, Coronavirus Disease 2019 (COVID-19) has emerged as a global pandemic. We aimed to investigate the clinical characteristics and analyzed the risk factors for prolonged viral RNA shedding. We retrospectively collected data from 112 hospitalized COVID-19 patients in a single center in Wuhan, China. Factors associated with prolonged viral RNA shedding (≥28 days) were investigated. Forty-nine (43.8%) patients had prolonged viral RNA shedding. Patients with prolonged viral shedding were older and had a higher rate of hypertension. Proinflammatory cytokines, including interleukin-2R (IL-2R) and tumor necrosis factor-α (TNF-α), were significantly elevated in patients with prolonged viral shedding. Multivariate analysis revealed that hypertension, older age, lymphopenia and elevated serum IL-2R were independent risk factors for prolonged viral shedding. This comprehensive investigation revealed the distinct characteristics between patients with or without prolonged viral RNA shedding. Hypertension, older age, lymphopenia and high levels of proinflammatory cytokines may be correlated with prolonged viral shedding.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33068796</PMID>
<DateCompleted><Year>2020</Year>
<Month>12</Month>
<Day>04</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1521-7035</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>221</Volume>
<PubDate><Year>2020</Year>
<Month>12</Month>
</PubDate>
</JournalIssue>
<Title>Clinical immunology (Orlando, Fla.)</Title>
<ISOAbbreviation>Clin Immunol</ISOAbbreviation>
</Journal>
<ArticleTitle>Proinflammatory cytokines are associated with prolonged viral RNA shedding in COVID-19 patients.</ArticleTitle>
<Pagination><MedlinePgn>108611</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S1521-6616(20)30771-3</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clim.2020.108611</ELocationID>
<Abstract><AbstractText>Since December 2019, Coronavirus Disease 2019 (COVID-19) has emerged as a global pandemic. We aimed to investigate the clinical characteristics and analyzed the risk factors for prolonged viral RNA shedding. We retrospectively collected data from 112 hospitalized COVID-19 patients in a single center in Wuhan, China. Factors associated with prolonged viral RNA shedding (≥28 days) were investigated. Forty-nine (43.8%) patients had prolonged viral RNA shedding. Patients with prolonged viral shedding were older and had a higher rate of hypertension. Proinflammatory cytokines, including interleukin-2R (IL-2R) and tumor necrosis factor-α (TNF-α), were significantly elevated in patients with prolonged viral shedding. Multivariate analysis revealed that hypertension, older age, lymphopenia and elevated serum IL-2R were independent risk factors for prolonged viral shedding. This comprehensive investigation revealed the distinct characteristics between patients with or without prolonged viral RNA shedding. Hypertension, older age, lymphopenia and high levels of proinflammatory cytokines may be correlated with prolonged viral shedding.</AbstractText>
<CopyrightInformation>Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gao</LastName>
<ForeName>Chun</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zhu</LastName>
<ForeName>Li</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jin</LastName>
<ForeName>Cheng Cheng</ForeName>
<Initials>CC</Initials>
<AffiliationInfo><Affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tong</LastName>
<ForeName>Yi Xin</ForeName>
<Initials>YX</Initials>
<AffiliationInfo><Affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Xiao</LastName>
<ForeName>Ai Tang</ForeName>
<Initials>AT</Initials>
<AffiliationInfo><Affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zhang</LastName>
<ForeName>Sheng</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China. Electronic address: aloof3737@126.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>10</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Clin Immunol</MedlineTA>
<NlmUniqueID>100883537</NlmUniqueID>
<ISSNLinking>1521-6616</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015375">Receptors, Interleukin-2</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C558899">lopinavir-ritonavir drug combination</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>2494G1JF75</RegistryNumber>
<NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>9008-11-1</RegistryNumber>
<NameOfSubstance UI="D007372">Interferons</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>O3J8G9O825</RegistryNumber>
<NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000080424" MajorTopicYN="N">Cytokine Release Syndrome</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003920" MajorTopicYN="N">Diabetes Mellitus</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007372" MajorTopicYN="N">Interferons</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008231" MajorTopicYN="N">Lymphopenia</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015375" MajorTopicYN="N">Receptors, Interleukin-2</DescriptorName>
<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
<QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017201" MajorTopicYN="N">Virus Shedding</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Coronavirus disease 2019</Keyword>
<Keyword MajorTopicYN="Y">Lymphopenia</Keyword>
<Keyword MajorTopicYN="Y">Proinflammatory cytokines</Keyword>
<Keyword MajorTopicYN="Y">Prolonged viral RNA shedding</Keyword>
<Keyword MajorTopicYN="Y">SARS-CoV-2</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>05</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>10</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>10</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>10</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>12</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>10</Month>
<Day>17</Day>
<Hour>20</Hour>
<Minute>8</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33068796</ArticleId>
<ArticleId IdType="pii">S1521-6616(20)30771-3</ArticleId>
<ArticleId IdType="doi">10.1016/j.clim.2020.108611</ArticleId>
<ArticleId IdType="pmc">PMC7554496</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Euro Surveill. 2020 Jan;25(3):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31992387</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Apr 30;382(18):1708-1720</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32109013</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2020 Oct;92(10):1755-1756</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32270882</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Open Forum Infect Dis. 2020 Mar 21;7(3):ofaa102</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32258207</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Immunol. 2020 Sep;218:108524</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32659373</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Total Environ. 2020 Aug 1;728:138812</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32335406</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Semin Immunopathol. 2017 Jul;39(5):529-539</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28466096</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Mar 19;382(12):1177-1179</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32074444</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):507-513</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32007143</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect. 2020 Jun;80(6):e14-e18</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32171866</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pathol. 2006 Nov;210(3):288-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17031779</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Virol. 2020 Jun;127:104346</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32361324</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Apr 7;323(13):1239-1242</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32091533</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2020 Apr;92(4):401-402</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31950516</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Virol. 2016 Sep 29;3(1):533-553</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27501259</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):762-768</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32161940</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Immunol. 2020 Sep;218:108517</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32585295</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Infect Dis. 2020 Aug;97:212-214</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32200109</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Exp Immunol. 2004 Apr;136(1):95-103</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15030519</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Apr 21;323(15):1502-1503</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32105304</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A15 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000A15 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidChloroV1 |flux= Main |étape= Corpus |type= RBID |clé= pubmed:33068796 |texte= Proinflammatory cytokines are associated with prolonged viral RNA shedding in COVID-19 patients. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:33068796" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a CovidChloroV1
![]() | This area was generated with Dilib version V0.6.38. | ![]() |